GV20 Therapeutics uses its proprietary STEAD (Simultaneous Target Evaluation and Antibody Discovery) platform to decode the natural B cell responses in patient tumors to rapidly identify novel ...

In response to this shift, companies are moving away from legacy, proprietary monitoring and observability solutions developed over a decade ago. Instead, they are adopting advanced, open ...

Next-generation KYC providers are harnessing AI to transform financial security and compliance as digital identity verification continues to evolve ...

DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into ...

CARD91, a leader in payment issuance, proudly announces the launch of its proprietary UPI Switch: Blitz--a platform designed ...

Telefonica Tech targeted a hike in genAI usage by businesses with a plug-and-play platform covering custom virtual assistants ...